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Pivotal results for the Medtronic Valiant Thoracic
Stent Graft System in the VALOR II trial
Ronald M. Fairman, MD,a J. Michael Tuchek, DO,b W. Anthony Lee, MD,c
Karthikeshwar Kasirajan, MD,d Rodney White, MD,e Manish Mehta, MD,f Sean Lyden, MD,g
Dipankar Mukherjee, MD,h and Joseph Bavaria, MD,a for the VALOR II Investigators, Philadelphia, Pa;
Chicago, Ill; Boca Raton, Fla; Concord and Torrance, Calif; Albany, NY; Cleveland, Ohio; and Falls Church, Va
Objective: We report 30-day and 12-month results of endovascular treatment with the Valiant Thoracic Stent Graft
System (Medtronic Vascular, Santa Rosa, Calif) in patients with descending thoracic aortic aneurysms of degenerative
etiology. The Valiant stent graft is an evolution of the Talent thoracic stent graft (Medtronic Vascular).
Methods: The VALOR II (Evaluation of the Clinical Performance of the Valiant Thoracic Stent Graft System in the
Treatment of Descending Thoracic Aneurysms of Degenerative Etiology in Subjects Who Are Candidates for Endovas-
cular Repair) was a prospective, nonrandomized, pivotal trial conducted at 24 U.S. sites with enrollment between
December 2006 and September 2009. Standard follow-up examinations, including physical examination, computed
tomography, and chest radiography, were at 1, 6, and 12 months, and annually through 5 years. VALOR II outcomes
were compared with those from the pivotal VALOR (Evaluation of the Medtronic Vascular Talent Thoracic Stent Graft
System for the Treatment of Thoracic Aortic Aneurysms) trial of the Talent stent graft, which enrolled 195 patients with
similar enrollment criteria.
Results: VALOR II enrolled 160 patients. Compared with VALOR patients, VALOR II patients had similar age and sex
distribution but higher rates of cardiovascular risk factors and significantly more severe modified Society for Vascular
Surgery/American Association for Vascular Surgery risk scores. Stent graft delivery and deployment were successful in
154 patients (96.3%). Outcomes at 30 days in VALOR II were perioperative mortality, 3.1%; major adverse events,
38.1%; paraplegia, 0.6%; paraparesis, 1.9%; and stroke, 2.5%. At 12 months, after the minimum sample size was reached,
151 patients were evaluated: aneurysm-related mortality was 4.0%, stent graft migration was 2.9%, and endoleak was
13.0%. Through 12 months, there were no ruptures, conversions to open surgery, secondary procedures due to endoleak
>30 days, or loss of stent graft patency. The Valiant stent graft was statistically noninferior to the Talent stent graft in
12-month all-cause mortality (12.6% vs 16.1%) and exceeded the primary effectiveness goal of 12-month successful
aneurysm treatment, defined as absence of aneurysm growth>5mm and of secondary procedures for type I/III endoleak
(97.4% vs 80.0%).
Conclusions: The VALOR II 12-month results demonstrate that the Medtronic Valiant thoracic stent graft is a safe and
effective treatment for patients with descending thoracic aortic aneurysms of degenerative etiology. (J Vasc Surg 2012;
56:1222-31.)
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COriginally modeled on devices designed for endovas-
cular abdominal aortic repair (EVAR), stent grafts for
thoracic EVAR (TEVAR) have evolved toward ever
greater anatomic specificity, and the latest-generation
thoracic devices promise improved performance with
respect to the unique characteristics of the aortic arch
and descending thoracic aorta—extreme tortuosity,
greater hemodynamic forces, remoteness from the sites
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Volume 56, Number 5 Fairman et al 1223procedures, including left subclavian artery (LSA) bypass
and cerebrospinal fluid (CSF) drainage.3-7
The Valiant Thoracic Stent Graft System (Medtronic
Vascular, Santa Rosa, Calif) is an evolution of the Talent
Thoracic Stent Graft System (Medtronic Vascular),8 with
new features specifically addressing TEVAR issues identi-
fied by earlier studies. Since 2005, when the device received
Conformité Européenne marking, the Valiant stent graft
has been used for repair of thoracic aortic lesions in clinical
practice outside the U.S.9-11
This report summarizes the pivotal 30-day and 12-
month results of the VALOR II (Evaluation of the Clinical
Performance of the Valiant Thoracic Stent Graft System in
the Treatment of Descending Thoracic Aneurysms of De-
generative Etiology in Subjects Who Are Candidates for
Endovascular Repair) trial. These results were compared
with those of the test arm of the pivotal study of the Talent
Thoracic Stent Graft, the VALOR (Evaluation of the
Medtronic Vascular Talent Thoracic Stent Graft System for
the Treatment of Thoracic Aortic Aneurysms) trial (Talent
control group).8
METHODS
Enrollment. The VALOR II trial was a prospective,
nonrandomized, multicenter clinical trial conducted in the
U.S., under an investigational device exemption (IDE), to
evaluate the safety and efficacy of the Valiant Thoracic Stent
Graft System for the treatment of descending thoracic
Table I. Anatomic and medical inclusion and exclusion cr
Inclusion criteria
● Age between 18 and 85 years
● SVS/AAVS criteria 0, 1, or 2
● Women with negative pregnancy test 7 days before implant
● A fusiform focal TAA 5 cm or 2 times nonaneurysmal aorta
● TAA 20 mm distal to origin of left common carotid artery and
● Proximal and distal nonaneurysmal neck diameter between 20 a
● Proximal and distal nonaneurysmal neck length 20 mm
● TAA confirmed by CTA/MRA with optional three-dimensional
● Able and willing to undergo follow-up imaging and examination
● Patent iliac and femoral arteries or can tolerate a vascular condu
delivery system
Exclusion criteria
● Planned placement of the covered portion of the stent graft in z
● TAA with contained rupture
● Connective tissue disease (eg, Marfan syndrome, medial degene
● Mycotic aneurysm or is suspected of having systemic infection
● Previous stent and/or stent graft or previous surgical repair in th
● Treatment of an infrarenal aneurysm at the time of implant
● History of bleeding diathesis, coagulopathy, or refuses blood tra
● Major surgical procedure 30 days before or after implant proc
● Myocardial infarction or cerebrovascular accident 3 months
● Currently participating in an investigational drug or device clinic
● Known allergy or intolerance to the device components
● Known hypersensitivity or contraindication to anticoagulants or
● Significant and/or circumferential aortic mural thrombus at prox
● Medical, social, or psychological problems that may preclude rec
limited life expectancy of 1 year
CTA, Computed tomography angiography; DTA, descending thoracic ao
Surgery/American Association for Vascular Surgery; TAA, thoracic aortic aaortic aneurysms (TAAs) of degenerative etiology (Na- bional Clinical Trial No. 00413231). All patients provided
ritten informed consent, and approval was obtained
rom the Institutional Review Board of each participat-
ng institution. Enrollment occurred fromDecember 2006
o September 2009 at 24 institutions across the U.S. (Ap-
endix I, online only). The patients were considered low-
isk candidates for elective surgical repair of TAAs and were
ow to moderate risk (0, 1, and 2) according to the modi-
ed criteria of the Society for Vascular Surgery (SVS)/
merican Association for Vascular Surgery (AAVS).12
The anatomic and medical inclusion and exclusion
riteria are presented in Table I. The inclusion and exclu-
ion criteria of VALOR II were similar to but slightly
ifferent from those for the pivotal VALOR trial of the
alent thoracic stent graft. Unlike VALOR,8 VALOR II
llowed enrollment of patients with previously treated ab-
ominal aortic aneurysms (AAAs), allowed the use of aortic
onduits in addition to iliac artery conduits, and did not
ermit enrollment of patients who had experienced a myo-
ardial infarction 3 months. Whereas VALOR allowed
nclusion of proximal and distal nonaneurysmal neck diam-
ters between 18 and 42 mm, VALOR II allowed a range
etween 20 and 42 mm, because 22-mm Valiant devices
ere not included for the IDE trial. All anatomic enroll-
ent criteria were assessed by site-reported vessel dimen-
ions and further reviewed by an independent physician
creening committee. In the report of results, however,
or focal saccular TAA or penetrating atherosclerotic ulcer
mm proximal to the origin of the celiac artery
mm
nstruction 4 months before screening
, 6, and 12 months, and annually thereafter
wing endovascular access to the aneurysmal site with the
or 1
)
A
ions
al
rast media that is not amenable to pretreatment
or distal attachment sites
of treatment or follow-up procedures and examinations or a
RA, magnetic resonance angiography; SVS/AAVS, Society for Vascular
sm.iteria
and/
20
nd 42
reco
s at 1
it allo
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Metrix Solutions, Inc, West Lebanon, NH).
Device description and deployment. The Valiant
stent graft system used in this trial was a modular, self-
expanding, tubular endoprosthesis (Fig 1) compressed and
preloaded into the Xcelerant Delivery System (Medtronic
Vascular), which consists of a single-use disposable catheter
with an integrated handle. The nitinol scaffolding of the
stent graft is composed of a series of serpentine five-peaked
springs stacked in a tubular configuration. The scaffolding
in this device is sewn to the outside of the graft material
(not the inside, as with the Talent device). The longitudinal
connecting bar of the Talent device has been eliminated,
and the spring spacing has been redesigned. Longer stent
graft components were made available for the Valiant de-
vice (up to 200 mm vs 130 mm for the original Talent
device).
As with the Talent device, the proximal Valiant stent
graft has a bare-spring configuration at the proximal end
(FreeFlo). The eight-peak configuration of the proximal
bare spring of the Valiant device has less flare than the
five-peak proximal bare spring configuration of the Talent
stent graft and is intended to distribute radial force across
more points of contact, resulting in less force per point. A
distal stent graft component has a closed web configuration
at the proximal end (no bare spring) and a closed web or an
Fig 1. The Valiant Thoracic Stent Graft.eight-peak bare-spring configuration at the distal stent end. mEnd points and definitions. Standard follow-up eval-
ations were performed at 1, 6, and 12 months, and
nnually through 5 years. Follow-up visits included com-
uted tomography scan, chest radiography, and physical
xamination. All imaging, with protocol-specified compo-
ents, was performed by the investigational sites, and all
nterim and mandated imaging performed within the first
ear of follow-up was submitted to the core laboratory for
eview and confirmation and for analysis of safety and
ffectiveness end points. Guidelines were provided for use
f magnetic resonance imaging, such as in patients with
mpaired renal function and for integrating results with
esults from the other imaging modalities.
The primary safety end point for VALOR II was all-
ause mortality within 12 months of the initial procedure.
he primary effectiveness end point was successful aneu-
ysm treatment at 12 months, which was defined as the
omposite of the absence of aneurysm growth 5 mm
etween the 30-day and 12-month follow-up visits and the
bsence of any type I or type III endoleak for which a
econdary procedure was performed before the 12-month
ollow-up visit or had been recommended by the physician
s of the 12-month visit.
Secondary end points30 days were successful delivery
nd deployment of the stent graft at the intended treatment
ite, perioperative mortality, paraplegia, paraparesis, sec-
ndary procedures due to endoleak after discharge, and
ig 2. Patient accountability and determination of the popula-
ion evaluable for end point analysis in the VALOR II (Evaluation
f the Clinical Performance of the Valiant Thoracic Stent Graft
ystem in the Treatment of Descending Thoracic Aneurysms of
egenerative Etiology in Subjects Who Are Candidates for Endo-
ascular Repair) trial of the Valiant Thoracic Stent Graft System.ajor adverse events (MAEs). Secondary end points 12
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vascular procedures due to endoleak between 30 days and
12months, conversion to open surgical repair, migration of
the stent graft relative to 30 days, loss of stent graft patency,
aneurysm rupture, endoleak at 12 months, and MAEs.
Aneurysm-related death was defined as any death oc-
curring30 days from initial implantation or at any time as
a consequence of an aneurysm rupture, conversion to open
repair, or any other secondary endovascular procedure as-
sociated with the aneurysm that was treated by the Valiant
stent graft, as evidenced by computed tomography scan,
angiography, or direct observation at surgery or autopsy.
Endoleaks were defined according to the well-established
type I to IV nomenclature,13 with an additional category
for type V/unknown. Migration was defined as 10 mm
proximal or distal movement of the stent graft relative to
fixed anatomic landmarks. Aneurysm expansion was de-
fined as 5-mm increase in diameter from the 30-day to
12-month follow-up visit.
Data management and statistical analysis. Summary
statistics presented for categoric variables are the number in
Table II. Baseline medical history
Medical history
VALOR
(n  160)
Cardiovascular
AAA 38.8 (6
Previous AAA repair 20.6 (3
Ascending thoracic aneurysm 8.1 (1
Angina 9.4 (1
Arrhythmia 31.3 (5
Carotid artery disease 28.1 (4
Congestive heart failure 11.9 (1
Coronary artery disease 44.4 (7
CABG 13.8 (2
Hypertension 93.8 (1
Myocardial infarction 21.3 (3
PCI 16.9 (2
Peripheral vascular disease 25.0 (4
COPD 35.0 (5
Renal insufficiency 16.3 (2
Cerebrovascular/neurologic
Transient ischemic attack 11.3 (1
Cerebrovascular accident 10.6 (1
Paraplegia 0.0 (0
Paraparesis 0.6 (1
Other abnormal body systems
Bleeding disorder 2.5 (4
Diabetes 21.3 (3
Gastrointestinal
complications
40.6 (6
Hyperlipidemia 73.8 (1
Tobacco use in last 10 yearsb 44.4 (7
AAA, Abdominal aortic aneurysm; CABG, coronary artery bypass graftin
intervention; VALOR, Evaluation of the Medtronic Vascular Talent Thorac
II, Evaluation of the Clinical Performance of the Valiant Thoracic Stent Gr
Etiology in Subjects Who Are Candidates for Endovascular Repair.
aAdjusted for Society for Vascular Surgery/American Association for Vascula
association statistic was used.
bFor VALOR, participants who answered “yes” to “tobacco use” and who
“tobacco use in last 10 years.”each category and the percentage of known values that this oumber represents. For continuous variables, the mean,
tandard deviation, and range are provided. P values were
alculated using standard tests, as noted. Kaplan-Meier
urves were used to plot freedom from event over time.
The primary safety end point, the rate of all-cause
ortality 12 months, was submitted to a noninferiority
omparison with that of the Talent control group using an
djusted odds ratio (OR) calculated using the Cochran-
antel-Haenszel test to control for SVS/AAVS scores, the
pper threshold of which was 2.25. The primary effective-
ess end point of successful aneurysm treatment at 12
onths was compared with a fixed value of 80%.
The VALOR II sample size was determined based on a
oal of achieving 80% statistical power at a one-sided
ignificance level of 5% to demonstrate the primary safety
nd effectiveness objectives. These calculations yielded a
inimum sample size of 150 subjects to evaluate the pri-
ary safety end point and a minimum sample size of 100 to
valuate the primary effectiveness end point. Statistical
nalyses were performed using R 2.5.1 software (R Foun-
ation for Statistical Computing http://www.r-project.
VALOR test arm
Pa) (n  195) % (n)
19.0 (37) .001
2.1 (4) .001
Not collected
14.4 (28) .094
26.7 (52) .602
5.6 (11) .001
8.7 (17) .546
40.5 (79) .928
10.3 (20) .466
87.2 (170) .186
13.8 (27) .117
5.6 (11) .002
16.4 (32) .091
36.9 (72) .426
17.4 (34) .479
7.7 (15) .471
9.7 (19) .958
1.0 (2) .388
0.5 (1) .984
2.6 (5) .994
15.9 (31) .426
53.8 (105) .006
43.6 (85) .001
50.3 (98) .333
PD, chronic obstructive pulmonary disease; PCI, percutaneous coronary
nt Graft System for the Treatment of Thoracic Aortic Aneurysms; VALOR
tem in the Treatment of Descending Thoracic Aneurysms of Degenerative
ery score of 0/1 vs 2/3. For nominal polychotomous variables, the general
olve date was 10 years ago were considered as “no” to the question ofII
% (n
2)
3)
3)
5)
0)
5)
9)
1)
2)
50)
4)
7)
0)
6)
6)
8)
7)
)
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)
4)
5)
18)
1)
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Demographics. The VALOR II trial enrolled 160 pa-
tients, and all 160 were included in the 30-day analyses (Fig
2). The 12-month analysis presented in this report had
been planned to be performed once a minimum sample size
of 150 had completed the 12-month interval visits. At the
time of the 12-month data analysis, the follow-up had been
completed for 151 patients. The 30-day and the 12-month
analyses both included three patients who did not receive
the study device due to vessel access failure. Patients were a
mean age of 72.2 9.1 years, 59.4% were men, and 86.3%
were white. Baseline medical history for the patients en-
rolled in VALOR II is presented in Table II. By SVS/AAVS
categories, one patient (0.6%) was in class 0, 17 (10.6%)
were in class 1, 140 (87.5%) were in class 2, and two (1.3%)
were in class 3.
Baseline anatomic etiologies were divided between
fusiform aneurysm in 103 (64.4%) and saccular aneurysm/
penetrating atherosclerotic ulcer in 57 (35.6%). No patient
had both morphologies. At enrollment, 50 patients
(31.3%) had aneurysm-related symptoms. The baseline
symptoms most frequently reported were back pain in 34
Table III. Acute procedural data
Variable VAL
Successful deployment and delivery 96.3 (154
Blood transfusion required 10.0 (16/
Blood loss during procedure, mL 277.0  4
Duration of implant procedure, min 119.7  5
Length of stay
Intensive care unit, hours 66.5  1
Overall hospital stay, days 6.1  8
Devices implanted per patient 1.8  0
LSA revascularization preimplant or at initial
procedure
13.8 (22/
Left subclavian transposition 1.3 (2/1
Carotid–subclavian bypass 12.5 (20/
Arterial access
Iliac/aortic conduit 15.0 (24/
Femoral/iliac artery 85.0 (136
Anesthesia
General 88.1 (141
Epidural 0.0 (0/1
Spinal 7.5 (12/
Local 4.4 (7/1
Cerebrospinal fluid drainage 53.8 (86/
LSA coveraged
Complete 27.4 (43/
Partial 5.1 (8/1
None 67.5 (106
LSA, Left subclavian artery; VALOR, Evaluation of the Medtronic Vascu
Aneurysms; VALOR II, Evaluation of the Clinical Performance of the V
Aneurysms of Degenerative Etiology in Subjects Who Are Candidates for E
Continuous data are shown as mean  standard deviation (range) and categ
aP value was calculated using the Fisher exact test.
bP value was calculated using Wilcoxon rank-sum test with normal approxim
cP value was calculated using two-sample t-test.
dLSA coverage was site-reported in VALOR II; in VALOR, LSA coverage w
and P value calculation.(21.3%) and chest pain in 25 (15.6%). cMean aneurysm length was 123.2  73.0 mm (range,
7.0-316.0 mm), mean proximal neck diameter was 32.5 
.2 (range, 21.0-51.5 mm), and mean maximum aneu-
ysm diameter was 57.0  11.0 mm (range, 31.4-97.7
m). There was partial proximal neck thrombus in 114
atients (71.3%), circumferential proximal neck throm-
us in 27 (16.9%), partial distal neck thrombus in 109
68.1%), and circumferential distal neck thrombus in 29
18.1%). Severe proximal neck calcification was found in
even patients (4.4%) and severe distal neck calcification in
hree (1.9%).
Procedure and hospital course. Acute procedural
nd clinical utility data for the VALOR II patients are
rovided in Table III. Vessel access was successful in 157
atients (98.1%). Delivery and deployment at the intended
ite was successful in 154 (96.3%) compared with 99.5% in
ALOR (P  .0490). A mean number of 1.8  0.8 stent
raft devices (range, 1-4) were implanted vs 2.7  1.3 in
ALOR (P  .0001). LSA coverage was complete in 43
atients (27.4% vs 19.9% in VALOR), 21 of whom were
evascularized, and partial in eight patients (5.1%), one of
hom was revascularized; 106 patients (67.5%) had no
II VALOR test arm P
) 99.5 (194/195) .0490a
22.7 (44/194) .0016a
(0-4000) 371.2  514.4 (10-3000) .4618b
2-310) 154.2  76.0 (34-615) .0001c
(0-1036) 46.8  114.3 (0-1101) .0001b
90) 6.4  11.5 (1-125) .0421b
2.7  1.3 .0001b
5.2 (10/194) .0082a
Not collected
Not collected
.1678a
21.1 (41/194)
) 78.9 (153/194)
.0059a
) 86.6 (168/194)
5.7 (11/194)
5.2 (10/194)
2.6 (5/194)
Not collected
.0358a
19.9 (32/161)
12.4 (20/161)
) 67.7 (109/161)
alent Thoracic Stent Graft System for the Treatment of Thoracic Aortic
Thoracic Stent Graft System in the Treatment of Descending Thoracic
scular Repair.
ata as percentage (n).
.
rted by the core laboratory; indeterminate values were excluded from tableOR
/160
160)
68.8
4.8 (3
12.3
.9 (1-
.8
160)
60)
160)
160)
/160
/160
60)
160)
60)
160)
157)
57)
/157
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minutes (range, 32-310 minutes) compared with 154.2
minutes in VALOR (P  .0001. Transfusion was required
in 16 patients (10%, vs 22.7% in VALOR; P .0016). The
mean dose of contrast medium was 150.1  97.3 mL
(range, 15-650 mL).
Mortality. On the primary safety end point of
VALOR II, 19 of the 151 evaluable patients (12.6%) died
12 months after implant (Table IV). The primary safety
objective of noninferiority comparison with the VALOR
results (31 of 192, 16.1%)8 was achieved (adjusted OR,
0.70; below the specified threshold). The Kaplan-Meier
survival analysis performed on the 12-month rate of all-
cause mortality for VALOR II (Valiant) vs VALOR (Tal-
ent) patients is presented in Fig 3.
Five of 19 deaths occurred30 days after implant: one
Table IV. MAEs for VALOR II patients at 30 days and 1
Category
All-cause mortality
Aneurysm-related mortality
Respiratory complications
Respiratory failure
Pneumonia
Atelectasis
Pulmonary embolism
Pulmonary edema
Renal complications
Renal insufficiency
Renal failure
Cardiac complications
Myocardial infarction
Unstable angina
New arrhythmia/cardiac arrest
Exacerbation of congestive heart failure
Neurologic complications
Stroke/cerebrovascular accident
Transient ischemic attack
Paraplegia
Paraparesis
Gastrointestinal complications
Bowel ischemia
Major bleeding complications
Major bleeding eventa
Coagulopathy
Vascular complications
AV fistula
Hematoma
Nonaortic vessel rupture/dissection
Aortic rupture/dissection
Embolism (not CVA/TIA/pulmonary)
Arterial occlusion
Retroperitoneal bleed
Thrombosis
Pseudoaneurysm
Vessel disruption
Aneurysm rupture
Patients with 1 MAE
CVA, Cerebrovascular accident;MAEs, major adverse events; TIA, transient
Thoracic Stent Graft System in the Treatment of Descending Thoracic Aneu
Repair.
aDuring or after the procedure.patient died at implant, one died of acute dissection, and whree died of single ormultiple organ failure. The difference
n survival based on presenting etiology was not statistically
ignificant. The five periprocedural deaths were considered
o be aneurysm-related according to the protocol definition
Table V). The site-assigned causes of deaths occurring
30 days in the 12-month analysis population are pre-
ented in Table VI.
One of the deaths 30 days was adjudicated as being
neurysm-related (Table V). This patient, a 79-year-old
iabetic woman with a complicated history of cardiovascu-
ar conditions, events, and procedures, had previously been
reated for an infrarenal AAA, had severely tortuous access
rteries, and a moderately tortuous aorta. She was im-
lanted with three thoracic stent grafts, with proximal
anding in zone 2. Two hours after the index procedure, the
atient experienced cardiac arrest due to LSA occlusion,
nths
0-30 days
% (n)
0-365 days
% (n)
3.1 (5/160) 12.6 (19/151)
3.1 (5/160) 4.0 (6/151)
9.4 (15/160) 14.9 (23/154)
4.4 (7/160) 7.1 (11/154
3.8 (6/160) 5.2 (8/154)
1.3 (2/160) 1.9 (3/154)
1.3 (2/160) 2.6 (4/154)
1.9 (3/160) 3.9 (6/154)
5.0 (8/160) 8.4 (13/154)
2.5 (4/160) 3.9 (6/154)
2.5 (4/160) 5.2 (8/154)
15.0 (24/160) 20.1 (31/154)
1.9 (3/160) 2.6 (4/154)
0.6 (1/160) 0.6 (1/154)
11.9 (19/160) 13.6 (21/154)
1.9 (3/160) 5.8 (9/154)
5.0 (8/160) 10.4 (16/154)
2.5 (4/160) 6.5 (10/154)
0.0 (0/160) 1.3 (2/154)
0.6 (1/160) 0.6 (1/154)
1.9 (3/160) 1.9 (3/154)
1.3 (2/160) 2.6 (4/154)
1.3 (2/160) 2.6 (4/154)
6.9 (11/160) 7.8 (12/154)
5.0 (8/160) 5.2 (8/154)
2.5 (4/160) 3.2 (5/154)
20.6 (33/160) 24.0 (37/154)
0.0 (0/160) 0.6 (1/154)
6.3 (10/160) 6.5 (10/154)
5.0 (8/160) 5.2 (8/154)
1.9 (3/160) 4.5 (7/154)
1.9 (3/160) 1.9 (3/154)
2.5 (4/160) 3.2 (5/154)
1.9 (3/160) 1.9 (3/154)
0.6 (1/160) 0.6 (1/154)
3.8 (6/160) 3.9 (6/154)
1.9 (3/160) 1.9 (3/154)
0.0 (0/160) 0.0 (0/154)
38.1 (61/160) 48.7 (75/154)
ic attack; VALOR II, Evaluation of the Clinical Performance of the Valiant
of Degenerative Etiology in Subjects Who Are Candidates for Endovascular2 mo
ischem
rysmsith a patent left internal mammary graft. After emergency
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November 20121228 Fairman et alleft carotid–subclavian artery bypass, she experienced a
series of cardiac and renal problems and died on postoper-
ative day 80, with the site-assigned proximate cause of
death ventricular arrhythmia and cardiac standstill (Table
VI). Her death was adjudicated as procedure-related and
thus, by definition, aneurysm-related. The Kaplan-Meier
survival analysis of aneurysm-related mortality in VALOR
II is presented in Fig 4.
By stepwise covariate analysis, the predictors of all-cause
mortality12 months were age80 years (OR, 10.15; P
.002), a history of congestive heart failure (OR, 5.96; P 
.013), history of myocardial infarction (OR, 12.28; P  .001),
history of tobacco use in the last 10 years (OR, 10.17; P 
.002), and larger proximal neck (OR, 1.15 for each addi-
tional millimeter; P  .032).
Major adverse events. One or more MAEs occurred
in 61 patients (38.1%) 30 days after implantation and in
75 patients (48.7%) 12 months (Table IV). The most
frequently experienced MAEs 30 days and 12 months
were vascular complications, which, with an incidence of
20.6% at 30 days, were comparable to the 21.0% rate
experienced by the VALOR Talent test-group patients.
The Kaplan-Meier estimate of freedom from MAEs 12
months was 52.8% (standard error, 4.0%). By stepwise
covariate analysis, the sole predictor of the incidence of
MAEs30 days after implant was the implantation of more
than one device (OR, 2.44; P  .011). The predictors of
the incidence of MAEs 12 months were age 80 years
(OR, 2.74; P  .026), female sex (OR, 2.94; P  .007),
Fig 3. Kaplan-Meier plot of 12-month freedom from all-cause
mortality for VALOR II (Evaluation of the Clinical Performance of
the Valiant Thoracic Stent Graft System in the Treatment of
Descending Thoracic Aneurysms of Degenerative Etiology in Sub-
jects Who Are Candidates for Endovascular Repair) patients im-
planted with the Valiant Thoracic Stent Graft vs VALOR (Evalu-
ation of the Medtronic Vascular Talent Thoracic Stent Graft
System for the Treatment of Thoracic Aortic Aneurysms) test-
group patients implanted with the Talent Thoracic Stent Graft.history of peripheral vascular disease (OR, 2.84; P .022), arocedure duration (OR, 1.01 for each additional minute;
 .012), and larger proximal neck (OR, 1.13 for each
dditional millimeter; P  .003).
Cerebrovascular accidents. Four patients (2.5%) ex-
erienced stroke30 days. Two of these patients, in whom
he determination of hemorrhagic stroke was based on
adiologic findings only, had proximal implantation in zone
, below the LSA, and had resolution of the stroke, without
reatment, before discharge. The remaining two patients
xperienced ischemic stroke and had ongoing disability up
o 12months or death. The LSA was completely covered in
ne of these patients with ischemic stroke (bovine arch
natomy) and was partially covered in the other patient.
either patient with ischemic stroke underwent LSA revas-
ularization and in neither was there complete or partial
overage of the left carotid artery by the proximal FreeFlo
tent graft.
Spinal ischemia. Paraplegia occurred in one patient
0.6%) 1 day after the index procedure (Table V). A CSF
rain had not been placed preoperatively in this patient.
ascular access had been obtained with an iliac conduit,
nd the proximal stent graft had been implanted distal to
he LSA. On postoperative day 1, after a sharp drop in
lood pressure, the patient was reintubated and transferred
o the intensive care unit. After the onset of paraplegia, a
umbar drain was placed. The patient was still active in the
rial at the 12-month follow-up but with permanent ad-
erse sequelae related to the continuing paraplegia. Three
atients (1.9%), none of whom had coverage of the LSA,
ad onset of paraparesis30 days. Overall, only one of the
our patients with paraplegia or paraparesis had complete
ecovery.
Aortic dissections. Retrograde type A aortic dissec-
ion was experienced by two patients 30 days after im-
lant and by another two between 30 days and 12 months.
n one of these patients, who died at day 3 after implant, the
ortic cross-section in the preoperative computed tomog-
aphy was not smooth, suggesting pre-existing disease at
he location of the proximal implantation site, although no
lear dissection was identified. The intraprocedural imaging
evealed dissection, which may have been caused by the
rocedural guidewire. Another successfully underwent an
pen surgical repair when the dissection was noted on
maging at day 4 after implant. Two patients who experi-
nced type A dissections 30 days died at 5 and 6 months
fter implant: one patient refused corrective surgery after
xperiencing acute onset of chest and neck pain, and the
ther fell off a scooter 9 days before experiencing chest pain
ssociated with the traumatic injury. A fifth type A dissec-
ion was focal and was an incidental finding at 10months in
patient who presented with diverticular sepsis and later
ied of respiratory failure. Through 12 months, two type B
ortic dissections occurred, both focal and both incidental
ndings.
Stent graft effectiveness. The 12-month primary ef-
ectiveness end point, a composite of the absence of aneu-
ysm growth5mm relative to 1month and the absence of
ny recommended or performed secondary procedures due
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Volume 56, Number 5 Fairman et al 1229to type I or type III endoleak, was achieved in 112 of the
evaluable 115 patients (97.4%). For the three patients who
did not meet the success criteria, two had aneurysm growth
5 mm, and one had a type I endoleak for which a
secondary procedure was recommended at the 12-month
visit.
Through 12 months of follow-up, there were no cases
of aneurysm rupture, loss of patency or integrity of the stent
graft, or conversion to open surgical repair (Table V).
Through 12 months, the core laboratory identified three
patients (2.9%) with stent migration10mm relative to 30
days. The distal stent graft in all three patients hadmigrated
10 mm proximally, and none of these patients experi-
enced an adverse event related to migration. No stent
Table V. Summary of secondary end points at 30 days and
Category
30 days
Safety end points
Perioperative mortality
Paraplegia
Paraparesis
One or more major adverse events
Effectiveness end point
Secondary procedure due to endoleak after discharge
12 months
Safety end points
Aneurysm-related mortality
Aneurysm rupture
Conversion to open surgical repair
1 MAE
Effectiveness end points
Endoleak at 12 months
Secondary procedure due to endoleak 30 days
Stent graft migration relative to 1 month
Loss of stent graft patency
MAE, Major adverse event; VALOR, Evaluation of the Medtronic Vascu
Aneurysms; VALOR II, Evaluation of the Clinical Performance of the V
Aneurysms of Degenerative Etiology in Subjects Who Are Candidates for E
aP value was calculated using the Fisher exact test.
Table VI. Site-assigned causes of deaths occurring 30
days in the 12-month analysis population (n  151)
Days to death Site-assigned cause of death
80 Ventricular arrhythmia/cardiac standstill
88 Myocardial infarction
163 Aortic dissection
163 Intracranial cerebral hemorrhage
191 Aortic dissection
230 Cerebrovascular accident
231 Severe coronary artery disease
259 Respiratory failure
300 Congestive heart failure
308 Gastrointestinal bleeding
339 Chronic obstructive pulmonary disease
340 End-stage renal disease
348 Respiratory failure
352 Cerebrovascular accidentfractures or graft fabric defects were documented. (At 30 days, the core laboratory identified three patients
2.2%) with type I endoleak and two (1.4%) with type III
ndoleak. At 12 months, there were three patients (3.0%)
ith type I endoleak and one (1.0%) with type III endoleak
months
VALOR II VALOR
Pa% (n) % (n)
.1 (5/160) 2.1 (4/195) .7367
.6 (1/160) 1.5 (3/195) .6302
.9 (3/160) 7.2 (14/195) .0236
.1 (61/160) 41.0 (80/195) .5877
.6 (1/157) 0.0 (0/194) .4473
.0 (6/151) 3.1 (6/192) .99
.0 (0/154) 0.5 (1/192) .99
.0 (0/154) 0.5 (1/192) .99
.7 (75/154) 53.6 (103/192) .3875
.0 (13/100) 12.2 (15/123) .99
.0 (0/143) 6.5 (12/186) .0015
.9 (3/105) 3.9 (4/103) .7199
.0 (0/100) 0.0 (0/107)
lent Thoracic Stent Graft System for the Treatment of Thoracic Aortic
Thoracic Stent Graft System in the Treatment of Descending Thoracic
scular Repair.
ig 4. Kaplan-Meier plot of 12-month freedom from aneurysm-
elated mortality for VALOR II (Evaluation of the Clinical Perfor-
ance of the Valiant Thoracic Stent Graft System in the Treatment
f Descending Thoracic Aneurysms of Degenerative Etiology in
ubjects Who Are Candidates for Endovascular Repair) patients
mplanted with the Valiant Thoracic Stent Graft vs VALOR (Eval-
ation of the Medtronic Vascular Talent Thoracic Stent Graft
ystem for the Treatment of Thoracic Aortic Aneurysms) test-
roup patients implanted with the Talent Thoracic Stent Graft.12
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November 20121230 Fairman et alrecommended for one of the patients with type I endoleak
at 12 months. Through the follow-up 12 months (24
months for one patient and 48 months for another, with
the third having withdrawn from the study due to travel
distance for follow-up), no secondary procedures have been
performed for the remaining two patients with type I
endoleak and one patient with type III endoleak at 12
months. Most endoleaks at 30 days and 12 months were
type II. One patient (0.6%) required a secondary endovas-
cular intervention after discharge but30 days to resolve a
type I endoleak. No additional secondary procedures were
performed 365 days compared with an occurrence of
6.5% (12 of 186) in VALOR (P  .0015).
DISCUSSION
In this trial, the Valiant Thoracic Stent Graft System
was safe and effective in the treatment of descending TAAs
of degenerative etiology in patients who were considered
low-risk candidates for surgical repair. At 12 months, the
rate of all-cause mortality in VALOR II was 12.6%, com-
paring favorably with the rate of 16.1% for Talent test-
group patients in the original VALOR study8 and confirm-
ing the hypothesis of the prespecified noninferiority
comparison. The VALOR II patients were considerably
sicker than the VALOR patients, with significantly higher
rates of AAA, previous AAA repair, carotid artery disease,
percutaneous coronary intervention, and hyperlipidemia
(Table II). The distribution of modified SVS/AAVS scores
was significantly different in VALOR II compared with
VALOR, with a greater percentage of high-severity scores
in the Valiant patients (P  .002).
Comparison of 30-day and 12-month secondary end
points also showed a consistent tendency for better out-
comes in VALOR II (Table V). Through 12 months in
VALOR II, the rate of aneurysm-related mortality was
4.0%, and there were no aneurysm ruptures, conversions to
open surgery, loss of stent graft patency, stent fractures, or
graft fabric defects. In the Talent VALOR trial, there was
one fatal aneurysm rupture, one successful conversion to
open surgical repair at 9 months due to stent graft infec-
tion, no loss of stent graft patency, and two cases of loss of
Table VII. Endoleaks for VALOR II patients at 30 days
and 12 months (core laboratory)
Device-related event
At 30 days At 12 months
(n  139) % (n) (n  100) % (n)
Endoleak of any type 15.8 (22) 13.0 (13)
Type I 2.2 (3) 3.0 (3)
Type II 8.6 (12) 7.0 (7)
Type III 1.4 (2) 1.0 (1)
Type IV 0.0 (0) 0.0 (0)
Type V/unknown 4.3 (6) 2.0 (2)
VALOR II, Evaluation of the Clinical Performance of the Valiant Thoracic
Stent Graft System in the Treatment of Descending Thoracic Aneurysms of
Degenerative Etiology in Subjects Who Are Candidates for Endovascular
Repair.stent graft integrity. The rate of stent graft migration Tetween 30 days and 12 months was 2.9% for VALOR II
atients vs 3.9% for VALOR patients. The 12-month rate
f retrograde type A dissection was 2.5% (4 of 160) for
ALOR II patients vs 1.5% for VALOR patients. These
ates of retrograde type A dissection are within the range
eported in other TEVAR device trials.14,15
Of particular note, only one secondary endovascular
rocedure was performed in VALOR II due to endoleak
365 days, whereas 17 Talent test-group patients in the
ALOR trial had secondary procedures within the same
ime frame, 14 of those to resolve endoleak. With the low
ate of secondary procedures in VALOR II, the composite
nd point of successful aneurysm treatment at 12 months
as achieved by 112 of the 115 evaluable patients (97.4%).
The incidence of spinal ischemia in VALOR II com-
ared favorably with that in VALOR, with paraplegia 30
ays in just one patient (0.6% in VALOR II vs 1.5% in
ALOR) and paraparesis in three (1.9% in VALOR II vs
.2% in VALOR). The use of CSF drains in 53.8% of
atients in VALOR II may have been a factor in this
utcome. In general, the relatively low rates of acute ad-
erse events—including the 2.5% incidence of stroke 30
ays (the rate in VALOR was 3.6%)—may have been sup-
orted by the comparatively short duration of the implant
rocedure for VALOR II patients, at a mean just under 2
ours compared with a mean of 2.5 hours in VALOR.
he availability of longer-length devices also may have
ontributed to these more favorable outcomes. The cova-
iate analysis determined that the implantation of more
han one device was a predictor for the incidence of MAEs
30 days.
Data fromworldwide experiences with the Valiant stent
raft have been reported in several articles, which describe
he use of the device in a wide spectrum of thoracic aortic
athologies.9,11,16 The results of these European studies,
hich include a broad array of thoracic aortic pathology,
annot be strictly compared with VALOR II, which en-
olled purely aneurysms of degenerative etiology.
Subsequent to the completion of enrollment in the
ivotal VALOR II trial, the delivery system for the Valiant
tent graft was updated from the Xcelerant to the Captivia,
hich adds a novel tip-capture mechanism and a hydro-
hilic coating on the graft cover. The Valiant stent graft
ith the Captivia delivery system (Valiant Captivia) re-
eived Conformité Européenne marking in September
009 and was approved by the U.S. Food and Drug Ad-
inistration in April 2011.
ONCLUSIONS
The VALOR II trial results support the use of the
aliant stent graft as a safe and effective treatment for
atients with descending TAAs who are low-risk candidates
or elective surgical repair. Despite the significant comorbidi-
ies of these patients, they experienced satisfactory all-cause
ortality at 30 days and 12months and low aneurysm-related
ortality at 12 months. The comparative safety of the
aliant device in a group of patients sicker than those in the
alent control group from the VALOR trial was supported
11
1
1
1
1
1
S
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Volume 56, Number 5 Fairman et al 1231by favorable acute procedural and 1-year outcomes. The
long-term safety and effectiveness of the Valiant stent graft
will be tracked through 5 years of follow-up for the
VALOR II patients.
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